201 related articles for article (PubMed ID: 33794377)
1. Identifying Novel Drug Targets by iDTPnd: A Case Study of Kinase Inhibitors.
Naveed H; Reglin C; Schubert T; Gao X; Arold ST; Maitland ML
Genomics Proteomics Bioinformatics; 2021 Dec; 19(6):986-997. PubMed ID: 33794377
[TBL] [Abstract][Full Text] [Related]
2. An integrated structure- and system-based framework to identify new targets of metabolites and known drugs.
Naveed H; Hameed US; Harrus D; Bourguet W; Arold ST; Gao X
Bioinformatics; 2015 Dec; 31(24):3922-9. PubMed ID: 26286808
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
4. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
5. Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects.
Chartier M; Morency LP; Zylber MI; Najmanovich RJ
BMC Pharmacol Toxicol; 2017 Apr; 18(1):18. PubMed ID: 28449705
[TBL] [Abstract][Full Text] [Related]
6. Novel Computational Approach to Predict Off-Target Interactions for Small Molecules.
Rao MS; Gupta R; Liguori MJ; Hu M; Huang X; Mantena SR; Mittelstadt SW; Blomme EAG; Van Vleet TR
Front Big Data; 2019; 2():25. PubMed ID: 33693348
[TBL] [Abstract][Full Text] [Related]
7. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
8. A computational approach to finding novel targets for existing drugs.
Li YY; An J; Jones SJ
PLoS Comput Biol; 2011 Sep; 7(9):e1002139. PubMed ID: 21909252
[TBL] [Abstract][Full Text] [Related]
9. Computational probing protein-protein interactions targeting small molecules.
Wang YC; Chen SL; Deng NY; Wang Y
Bioinformatics; 2016 Jan; 32(2):226-34. PubMed ID: 26415726
[TBL] [Abstract][Full Text] [Related]
10. A large-scale computational approach to drug repositioning.
Li YY; An J; Jones SJ
Genome Inform; 2006; 17(2):239-47. PubMed ID: 17503396
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Target-specific compound selectivity for multi-target drug discovery and repurposing.
Wang T; Pulkkinen OI; Aittokallio T
Front Pharmacol; 2022; 13():1003480. PubMed ID: 36225560
[TBL] [Abstract][Full Text] [Related]
13. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
14. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
[TBL] [Abstract][Full Text] [Related]
15. Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions
Paludetto MN; Stigliani JL; Robert A; Bernardes-Génisson V; Chatelut E; Puisset F; Arellano C
Chem Res Toxicol; 2020 Jan; 33(1):181-190. PubMed ID: 31535851
[TBL] [Abstract][Full Text] [Related]
16. Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing.
Lim H; Poleksic A; Yao Y; Tong H; He D; Zhuang L; Meng P; Xie L
PLoS Comput Biol; 2016 Oct; 12(10):e1005135. PubMed ID: 27716836
[TBL] [Abstract][Full Text] [Related]
17. Rapid computational identification of the targets of protein kinase inhibitors.
Rockey WM; Elcock AH
J Med Chem; 2005 Jun; 48(12):4138-52. PubMed ID: 15943486
[TBL] [Abstract][Full Text] [Related]
18. Activity-based kinase profiling of approved tyrosine kinase inhibitors.
Kitagawa D; Yokota K; Gouda M; Narumi Y; Ohmoto H; Nishiwaki E; Akita K; Kirii Y
Genes Cells; 2013 Feb; 18(2):110-22. PubMed ID: 23279183
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase inhibitors: contributions from structure to clinical compounds.
Johnson LN
Q Rev Biophys; 2009 Feb; 42(1):1-40. PubMed ID: 19296866
[TBL] [Abstract][Full Text] [Related]
20. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.
Hasinoff BB; Patel D
Toxicol Appl Pharmacol; 2010 Dec; 249(2):132-9. PubMed ID: 20832415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
